Patients studied A series of 356 patients attending the Centre for Rheumatic Diseases in Glasgow was studied. The age and sex distribution and clinical diagnosis are shown in Table II . The 307 patients with RA had "definite" or "classical" disease by the 1958 criteria of the American Rheumatism Association (Ropes, Bennett, Cobb, Jacox, and Jessar, I959) . The following clinical details were recorded in the patients with RA in addition to the age and sex of the patient: duration of arthritis, presence of subcutaneous nodules, articular score (Co-operating Clinics Committee of the American Rheumatism Association, I965) and functional grade and x-ray stage (Steinbrocker, Traeger, and Batterman, I949) (Table III) . The following laboratory investigations were performed: haemoglobin concentration, erythrocyte sedimentation rate, serum albumin and globulin concentrations, sheep cell agglutination and latex fixation tests for rheumatoid factor, immunofluorescence tests for antinuclear factor (Beck, I96I) , serum calcium and phosphorus concentrations, go min. post-prandial blood sugars, and in some patients serum cholesterol determinations and serological tests for syphilis (Table III, (Williamson, Cant, Mason, Greig, and Boyle, I967) . Each patient had at least two ophthalmological examinations and those who continued to take oral corticosteroid drugs have been examined at 3-monthly intervals for up to 2 years. Patients who had received oral corticosteroid therapy in the past, but were not receiving corticosteroid therapy at the time of their first attendance, were examined on two further occasions at 3-monthly intervals. Only four patients were not examined by the slit lamp because of the severity of their rheumatoid disease. The criteria for diagnosing and classifying PSC were those suggested by Crews (1963) .
Grade I PSC occasional subcapsular opacities or vacuoles in the central region with or without polychromatic lustre and distortion of specular reflex.
Grade 2 PSC small clusters of opacities which remain discrete. Measurements of the intraocular pressure were made by applanation tonometry on all of the corticosteroid-treated patients and on IOO of the non-corticosteroid-treated patients (62-5 per cent.).
Whenever the intraocular pressure was found to be greater than 20 mm. applanation tonometry, the patient was admitted to hospital and the following tests were carried out: 24-hour intraocular pressure measurements at 4-hourly intervals, water-drinking tests, mydriatic tests, visual field examinations, and gonioscopy to determine the state of the angle of the anterior chamber. If glaucoma was still suspected then tonography was subsequently arranged.
Results

Rheumatoid arthritis group
The results in the 307 patients are summarized in Table IV . The diagnosis of PSC was made in seventeen patients who had received oral corticosteroids and in one patient who had never at any time received oral corticosteroids or corticotrophin therapy (Table IV) . (Crews, I963) . Ophthalmoscopic examination revealed no abnormalities of the fundi. The patient was not myopic. Six of the I48 steroid-treated rheumatoid arthritis patients had raised intraocular pressures on at least one occasion. All of these patients and the three in the non-steroidtreated group (Table IV) were screened for glaucoma as described above. Only one patient had both PSCs and bilateral raised pressures and he was the only patient judged to have glaucoma induced by systemic steroid therapy. The patient was a 45-year-old male rheumatoid arthritic who had received eight tablets of Medrone per day for 8 years. He had no family history of ocular disorders and had no siblings. His pressures were 40 mm. Hg applanation in both eyes and he had Grade II PSCs. Both discs were grossly cupped and atrophic, his fields being reduced within the IO1 isopter to Io mm. white targets at one metre from the Bjerrum screen. The angles of the anterior chambers were open and no abnormalities in the trabecular meshwork were detected. The outflow of aqueous humour from the anterior chamber was markedly reduced. When the systemic steroids were reduced his intraocular pressures fell. However, the withdrawal of steroids had to be reversed and his intraocular pressures rose once again. In all, three attempts were made to reduce the steroid intake and on each occasion the intraocular pressure fell only to rise again with increased steroid dosage. In between each attempt the intraocular pressures were controlled with miotics. Finally he was weaned off steroids and the intraocular pressure has remained normal on miotics three times a day for I year. When miotics are withdrawn his intraocular pressures rise to 26 to 28 mm. Hg but never to the previous levels of 40 mm. Hg recorded while on systemic steroids. The other five steroid-treated patients proved to be within normal limits. One of the three nonsteroid-treated patients had chronic simple glaucoma; the other two were judged to be normal. Table III shows that both groups of patients were well matched in respect of age, sex, duration of disease, functional grade, x-ray stage, articular index, and the presence or absence of subcutaneous nodules. In terms of the laboratory data, that is, rheumatoid factor, haemoglobin concentration, erythrocyte sedimentation rate, serum albumin and globulin concentrations, and go min. post-prandial blood sugars (Table III) , the groups compared favourably. The serum calcium was higher in the steroid-treated than in the non-steroid-treated group of patients.
22 of the 148 steroid-treated (13-6 per cent.) and 23 of the i59 non-steroid-treated patients (03.7 per cent.) had keratoconjunctivitis sicca (38 females and 7 males).
Seven of the 307 patients with RA were also suffering from uveitis (2-3 per cent.). One of the seven also had scleritis. Five of the seven patients had received long-term oral corticosteroid therapy, and in each of them PSC had developed in the eye or eyes showing evidence of uveitis. No PSC was present in either of the two remaining patients who had never received systemic steroid therapy (Table V) . (Table II) , of whom six had been treated with oral corticosteroid therapy by their family doctors in the belief that they were suffering from RA. Two of the corticosteroid-treated patients developed PSC, but none of the 26 patients who had never received oral corticosteroids (Table IV) . Of the three osteoarthritic patients who had raised intraocular pressures on one occasion (Table IV) , one had chronic simple glaucoma and the others were normal.
Four of the female patients with osteoarthritis (all aged 62 years) also had keratoconjunctivitis sicca; none of them had received systemic steroids.
Miscellaneous group
Sixteen patients presented with five other disorders (Table IV) . None of them was found to have PSC. One patient with Still's disease had kerato-conjunctivitis sicca and she had never received systemic corticosteroid therapy.
Discussion
PSCs were found in twenty and glaucoma was detected in three of the 356 patients attending the Centre for Rheumatic Diseases in Glasgow. In all but one case of PSC the patients had received long-term oral corticosteroid therapy. Only one case of glaucoma was attributed to systemic steroid therapy.
Rheumatoid arthritis group
Ten of I48 (6 per cent.) corticosteroid-treated rheumatoid arthritic patients and one of I59 (o 6 per cent.) non-corticosteroid-treated patients had developed PSC. The difference is statistically significant (X2 = 8-33; P <-OOI). PSC was found more frequently in the series of patients on long-term steroid therapy examined by Black and others (I960) (39 per cent.), Giles and others (I962) (37 per cent.), Crews (I963) (35 per cent.), Spencer and Andelman (I965) (6o per cent.), and Furst and others (I966) (IO-5 per cent.). In all these reports and in the present study, the incidence of cataract rose with higher dosage and longer duration of systemic corticosteroid therapy. There was no evidence of steroid overdosage in any of the patients who had developed PSC as judged by excessive increase in weight, moon facies, pitting oedema, low serum potassium, or excessive osteoporosis. However, the mean serum calcium level in the steroid-treated patients was 4-82 + o 9 mEq./litre, and in the non-steroid-treated patients it was 4-53 + I 2 mEq./'litre ("t" = 8-92; P <o0ooi). The steroid-treated patients had serum calcium levels significantly higher than the non-steroid-treated patients. The serum calcium levels of the steroid-treated patients with PSC did not, however, differ significantly from those in the steroid-treated patients as a whole.
Two clinical problems confronted the ophthalmologists in this study. First the detection of the posteriorly-placed lens opacities, and secondly their differentiation into steroidinduced and other types. Iridescent changes in the posterior subcapsular region with no other corroborative evidence of lens pathology were ignored because their detection was very much a matter of opinion. Iridescent changes were recorded by Black and others (I960) but were only mentioned by Crews (I963) to be discarded as too subjective. The workers in this present study agree with the latter opinion. The diagnosis of steroidinduced PSC depends on the exclusion of all other possible causes of posteriorly-placed lens opacities*. There is considerable overlap in the use of the terms posterior subcapsular cataract and posterior cortical cataracts and this may account in part for the conflicting reports mentioned above. Gordon and others (i96I) list as the commonest causes of PSC senility or pre-senility, uveitis, and retinitis pigmentosa. Most other workers would describe the senile lens changes as posterior cortical cataract in the first instance. Thus in this study all causes of PSC or posterior cortical cataract were considered before the diagnosis of steroid PSC was made. Seven patients who had PSC had evidence of uveitis and one other patient with PSC was a high myope. One patient had retinitis pigmentosa and another diabetes mellitus, but neither had cataract. Since most of the patients had been referred to the Centre for Rheumatic Diseases from many sources, it was not possible to estimate the x-ray dosage to which they had been subjected. No correlation between the incidence of PSC and exposure to x rays has been found to date (Black and others, I960; Toogood and others, I962), but it must be recorded that radiation and steroid cataracts are clinically identical. In this series of patients, the incidence of PSC was highest in those steroid-treated patients who had had rheumatoid arthritis for more than 9 years, and who could be expected to have had frequent x-ray examinations. Radiation cataract is caused by the direct effect of x rays on the subcapsular epithelium resulting in deranged mitotic activity. There is a latent period of 2 to 12 years before lens opacities appear. Not infrequently patients with RA require x-ray examinations of the cervical region, and scatter of x rays to the orbits is conceivable. The pathology of two lenses with steroid-induced cataract has been described (Black and others, I960; Crews, I963) and in both cases the epithelium near the equator and the nuclear bow *Ihesc iiclucle uvelitis, senility ()I pre-senility, myopia, retiniitis pigmentosa, ra(liationi, hypoparatlh roidism, (liabetes IllellituLs, atopic (lermnatitis, nx otouia congenita, and(l inigestioni of other toxic substances. appeared to be normal. In radiation cataract mitosis disappears in the epithelium near the equator, aberrant cells develop, and the nuclear bow is deranged. Radiation could excite an initial lesion and steroids could potentiate the effect of that radiation on the subcapsular epithelium. Thus a smaller than usual cataractogenic dose of x rays could start off a PSC leaving the nuclear bow apparently normal. In this context we note that two attempts to produce PSC in rats by feeding them with the equivalent of a large dose of prednisolone (von Sallmann, Caravaggio, Collins, and Weaver, 1960; Spencer and Andelman, I965) have failed. It may be possible to produce "steroid" PSCs in animals previously or simultaneously exposed to subcataractogenic doses ofx rays. Bettman, Fung, Webster, Noyes, and Vincent (i 968) were unable to demonstrate that corticosteroids increased the cataractogenic effect of dinitrophenol, xylose, triparanol, or radiation. However, four of fifty corticosteroid-treated rabbits developed lens opacities in the nonirradiated eye, whereas none of 25 non-corticosteroid-treated rabbits developed cataract in the non-irradiated eye. These authors felt that this difference was of questionable significance. A striking acceleration in the formation of galactose cataract was demonstrated by these workers in corticosteroid-treated rats.
Posterior subcapsular cataracts were most often demonstrated in the steroid-treated patients who had suffered from rheumatoid arthritis for more than 9 years and whose disease had reached an advanced stage radiologically (Table VI) . Both stage and duration of the disease were accurately known in I29 of the I48 steroid-treated patients (Table III) . Five of the 6I steroid-treated patients (9 3 per cent.) who had had RA for more than 9 years had PSC, whereas only two of the 69 patients who had had RA for less than 9 years (2.9 per cent.) had steroid cataracts.
These findings could mean either that corticosteroid drugs produce PSC in some patients or that severe RA may cause the condition. The available data suggest that the first of these probabilities is correct, for there was a very significant relationship between Five of 6i over 9 years (9.3 per cent. (Table VII) . Glaucoma was detected in one of the 148 patients on systemic steroid therapy. This patient also had PSC and had been taking the equivalent of 40 mg. prednisolone a day for 8 years. Glaucoma induced by systemic steroid therapy was diagnosed only after it was demonstrated that a fall in the intraocular pressure accompanied a reduction in steroid intake and a rise in intraocular pressure followed increased steroid intake. The most tragic feature of this patient's case was the complete absence of visual symptoms until4 months beforehisfirst ocular examination, yet the deeply cupped optic discs and gross visual field loss represented pathology of several years' duration. The rise in intraocular pressure was caused by a fall in the facility of outflow of aqueous from the anterior chamber of the eye. The angle of the anterior chamber appeared to be normal. In this respect the patient had eyes like those of a patient suffering from chronic simple glaucoma where no adhesions of peripheral iris have occurred. However, we do not know the relationship between systemic steroid therapy and any rise in the intraocular pressure in patients known to have or to be predisposed to chronic simple glaucoma. It may be that this patient would have developed chronic simple glaucoma in time without the help of systemic steroids. The patient had no siblings or close relatives and so it was not possible to determine any hereditary predisposition to glaucoma. On the other hand, his intraocular pressures returned to almost normal levels on withdrawal of the systemic steroids suggesting that the Medrone was playing a major part in the reduction of aqueous outflow. Further, he had developed steroid-induced PSCs indicating that the systemic steroids had adversely affected the functioning of his eyes at least as far as the maintenance of lens clarity was concerned.
Systemic steroids may be prescribed for patients with arthritis who also develop anterior uveitis. Seven patients in this series were found to have uveitis and five of these were receiving long-term oral corticosteroids. These five patients developed PSC and in one case the cataract progressed rapidly to complete maturity in the presence of continued uveal inflammation. There was no evidence in this small group that systemic steroids had inhibited the course of the intraocular inflammation. Each of the patients with uveitis and PSC had been given oral steroids for 2 to IO years; each had severe rheumatoid arthritis and had received large doses of prednisolone or its equivalent. The remaining two patients with uveitis and without PSC had equally severe arthritis but had not been given oral steroids. There was no significant difference in age between the two groups: mean 58-5 years (Table V) . Although the group of patients is small we may conclude that caution should be observed in prescribing systemic steroids as a specific measure in patients with rheumatoid arthritis and uveitis. None of these patients had glaucoma.
Osteoarthritis
Two of the six patients with osteoarthritis who had received long-term corticosteroid therapy developed PSC. This would substantiate the findings of Crews (I963), of "steroid-induced" cataracts in diseases other than rheumatoid arthritis and further suggests that oral steroid therapy is a major factor in the aetiology of the lens opacities. One patient, not treated with steroids, had chronic simple glaucoma.
Miscellaneous conditions
Neither cataracts or glaucoma were found in any of these patients. No conclusions can be drawn as the number of patients was small. Summary 356 patients attending the Centre for Rheumatic Diseases, Glasgow, were examined for posterior subcapsular cataracts and glaucoma. Approximately one half of them had been treated with long-term systemic corticosteroids and a definite relationship was found between the dose and duration of systemic steroid therapy and the incidence of cataract. Only one case of glaucoma induced by systemic steroids could be demonstrated with certainty, and this occurred in a patient who had had the equivalent of 40 mg. prednisolone a day for 8 years.
A possible relationship between exposure to x rays, systemic steroid therapy, and posterior subcapsular cataracts is discussed.
